Overview of Insider Activity#
On Tuesday, significant insider trading activities were reported for various U.S. stocks, highlighting notable purchases at Abbott Laboratories and Traws Pharma, among others.
Major Buys at Traws Pharma#
OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, key shareholders in Traws Pharma, Inc. (NASDAQ:TRAW), disclosed a substantial purchase of the company's common stock. On April 16, 2026, they acquired 597,729 shares at $1.67 each, totaling nearly $998,207. Currently, Traws Pharma's stock trades at $1.21, reflecting a decline of about 28% from the purchase price. This transaction was part of a larger private placement, which also included warrants allowing for the purchase of up to 2,988,645 additional shares at a price of $1.673 per share.
Abbott Laboratories Insider Purchase#
Daniel J. Starks, a director at Abbott Laboratories (NYSE:ABT), bought 10,000 shares of the company on April 27, 2026, for a total of $926,537. The shares were purchased at an average price of $92.65, with prices ranging from $92.43 to $93.04. This purchase is noteworthy as Abbott's stock is currently near its 52-week low of $90.72, down approximately 24% year-to-date. Additionally, Mr. Starks received a grant of 2,286 shares as part of Abbott's 2026 Incentive Stock Program, which will be paid out under specific conditions.
Lamb Weston Holdings CFO Purchase#
James D. Gray, the Chief Financial Officer of Lamb Weston Holdings, Inc. (NASDAQ:LW), also made headlines by purchasing 4,556 shares at $43.85 each on April 27, 2026, amounting to $199,780. Following this acquisition, Mr. Gray holds a total of 59,741 shares. Lamb Weston’s stock is currently trading around $43.08, down about 33% over the past six months, and is assessed as overvalued based on Fair Value analysis.
Conclusion#
These insider transactions provide insights into the confidence that company executives and significant shareholders have in their respective firms, despite recent market fluctuations.